The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70735 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2026. Written by Laurie-Rose Dubé and 10 co-authors. Institution: Faculty of Medicine, McGill University, Montreal, Quebec, Canada. Major MEDLINE topics: Colitis, Ulcerative, Leukocyte L1 Antigen Complex, Feces. Cited 2 times so far (Crossref); 31 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Endoscopic and histologic evaluation is part of routine clinical practice to confirm the presence of active disease in ulcerative colitis. Faecal calprotectin (FCAL) levels show a positive correlation with endoscopic indices, relapse, and response to treatment. Existing studies have not clearly determined cut‐off values for endoscopic and histologic remissions.
Aims
Our study aims to determine an optimal FCAL threshold for discriminating between endoscopic and histologic active disease and remission in UC, based on the Mayo Endoscopic Score (MES) and the Geboes Histologic Score.
Methods
We performed a pooled analysis of retrospective and prospective studies of patients with UC from four academic centres. Key inclusion criteria were adult UC patients undergoing colonoscopy, with FCAL measurements. Receiver operating characteristic curves were computed on 80% of the data using 5‐fold cross‐validation to determine the optimal FCAL threshold for predicting active UC based on specificity (spec) and sensitivity. Optimal thresholds were then tested on the remaining 20% of the data. Active endoscopic disease was assessed using MES 0–1 versus 2–3 and MES 0 versus 1–3, and active histologic disease or remission was evaluated using GHS < 3.1 versus GHS ≥ 3.1 and GHS ≤ 2.0 versus GHS > 2.0.
Results
A total of 741 patients with UC were included in our analysis. For MES 0 versus 1‐2‐3, the AUC was 0.716 (95% CI: 0.701–0.731, p < 0.0001) with an optimal threshold of 154.3 μg/g (specificity: 0.69 [95% CI: 0.65–0.72], sensitivity: 0.64 [95% CI: 0.60–0.69]). For MES 0–1 versus 2–3, the AUC increased to 0.802 (95% CI: 0.797–0.807, p < 0.0001), with an optimal FCAL threshold of 234.6 μg/g (specificity: 0.74 [95% CI: 0.74–0.75], sensitivity: 0.69 [95% CI: 0.62–0.75]). For GHS ≤ 2.0 versus GHS > 2.0, the AUC was 0.656 (95% CI: 0.647–0.664, p < 0.0001), with an optimal threshold of 117.6 μg/g (specificity: 0.61 [95% CI: 0.56–0.66], sensitivity: 0.59 [95% CI: 0.56–0.63]). For GHS < 3.1 vs. GHS ≥ 3.1, the AUC was 0.752 (95% CI: 0.743–0.762, p < 0.0001), with an optimal threshold of 166.2 μg/g (specificity: 0.69 [95% CI: 0.66–0.73], sensitivity: 0.69 [95% CI: 0.63–0.76]). Given the high AUC for MES 0–1 vs. MES 2–3, we tested different FCAL thresholds from the literature and propose a threshold of 170 μg/g to maximize sensitivity (sensitivity: 0.801 [95% CI: 0.729–0.873], specificity: 0.648 [95% CI: 0.641–0.656], LR+ 2.311 [95% CI: 2.001–2.670], LR‐ 0.289 [95% CI: 0.196–0.427], accuracy 67.62% [95% CI: 65.95–69.30]) and limit the proportion of false negatives.
Conclusions
Our study demonstrates that FCAL can predict both active endoscopic and histological disease with acceptable sensitivities and specificities. The proposed cut‐off values will help guide clinical practice to achieve the recommended treatment outcomes. Further studies are warranted to validate our results.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
- Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, Quebec, Canada.
- Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
- Institute of Pharmacology and Therapeutics, Porto, Portugal.
- Brooke Army Medical Center, Division of Gastroenterology and Hepatology, San Antonio, Texas, USA.
- Department of Gastroenterology, Hospital Universitari de Bellvitge-Institut D'investigació Biomédica de Bellvitge, Barcelona, Spain.
ORCID profiles: Laurie-Rose Dubé, Waqqas Afif
Cite
APA
Dubé, L. R., Sorin, M., Allez, M., Afif, W., Bitton, A., Lakatos, P. L., Wild, G., Magro, F., Patel, A., Guardiola, J., & Bessissow, T. (2026). The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70735
Vancouver
Dubé LR, Sorin M, Allez M, Afif W, Bitton A, Lakatos PL, et al. The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70735
BibTeX
@article{Dub2026,
author = {Dubé, Laurie-Rose and Sorin, Mark and Allez, Matthieu and Afif, Waqqas and Bitton, Alain and Lakatos, Peter L and Wild, Gary and Magro, Fernando and Patel, Anish and Guardiola, Jordi and Bessissow, Talat},
title = {The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70735}
}
EUVIMED